Katherine A McGlynn1, George W Divine2, Vikrant V Sahasrabuddhe3, Lawrence S Engel4, Ashley VanSlooten2, Karen Wells2, Marianne Ulcickas Yood5, Sharon Hensley Alford2. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. Electronic address: mcglynnk@mail.nih.gov. 2. Department of Public Health Sciences, Henry Ford Health Systems, Detroit, MI, United States. 3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. 4. Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States. 5. Boston University, Boston, MA, United States.
Abstract
PURPOSE: Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are medications widely prescribed to reduce cholesterol levels. Observational studies in high-risk populations, mostly in Asia, have suggested that statins are associated with a reduced risk of hepatocellular carcinoma (HCC). The current study sought to evaluate the association of statin use and HCC in a U.S.-based, low-risk, general population. METHODS: A nested case-control study was conducted among members of the Health Alliance Plan HMO of the Henry Ford Health System enrolled between 1999 and 2010. Electronic pharmacy records of statin use were compared among tumor registry-confirmed cases of HCC (n=94) and controls (n=468) matched on age, sex, diagnosis date, and length of HMO enrolment. RESULTS: In multivariate analyses, ever-use of statins was significantly inversely associated with development of HCC (Odds ratio (OR): 0.32, 95%CI: 0.15-0.67). No clear dose-response relationship was evident as statin use for <2 years (OR=0.32, 95%CI=0.13-0.83) and >2 years (OR=0.31, 95CI%=0.12-9.81) resulted in very similar ORs. CONCLUSIONS: The use of statins among populations in low-risk HCC areas may be associated with decreased risk of HCC. Published by Elsevier Ltd.
PURPOSE: Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are medications widely prescribed to reduce cholesterol levels. Observational studies in high-risk populations, mostly in Asia, have suggested that statins are associated with a reduced risk of hepatocellular carcinoma (HCC). The current study sought to evaluate the association of statin use and HCC in a U.S.-based, low-risk, general population. METHODS: A nested case-control study was conducted among members of the Health Alliance Plan HMO of the Henry Ford Health System enrolled between 1999 and 2010. Electronic pharmacy records of statin use were compared among tumor registry-confirmed cases of HCC (n=94) and controls (n=468) matched on age, sex, diagnosis date, and length of HMO enrolment. RESULTS: In multivariate analyses, ever-use of statins was significantly inversely associated with development of HCC (Odds ratio (OR): 0.32, 95%CI: 0.15-0.67). No clear dose-response relationship was evident as statin use for <2 years (OR=0.32, 95%CI=0.13-0.83) and >2 years (OR=0.31, 95CI%=0.12-9.81) resulted in very similar ORs. CONCLUSIONS: The use of statins among populations in low-risk HCC areas may be associated with decreased risk of HCC. Published by Elsevier Ltd.
Authors: Marie-France Demierre; Peter D R Higgins; Stephen B Gruber; Ernest Hawk; Scott M Lippman Journal: Nat Rev Cancer Date: 2005-12 Impact factor: 60.716
Authors: Ted Bader; Javid Fazili; Mohammed Madhoun; Christopher Aston; Diane Hughes; Syed Rizvi; Ken Seres; Muhammad Hasan Journal: Am J Gastroenterol Date: 2008-04-14 Impact factor: 10.864
Authors: Gary D Friedman; E Dawn Flick; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel Journal: Pharmacoepidemiol Drug Saf Date: 2008-01 Impact factor: 2.890
Authors: Katherine A McGlynn; Katrina Hagberg; Jie Chen; Barry I Graubard; W Thomas London; Susan Jick; Vikrant V Sahasrabuddhe Journal: J Natl Cancer Inst Date: 2015-02-26 Impact factor: 13.506
Authors: Tracey G Simon; Ann-Sofi Duberg; Soo Aleman; Hannes Hagstrom; Long H Nguyen; Hamed Khalili; Raymond T Chung; Jonas F Ludvigsson Journal: Ann Intern Med Date: 2019-08-20 Impact factor: 25.391
Authors: Mara M Epstein; George Divine; Chun R Chao; Karen E Wells; Heather Spencer Feigelson; Delia Scholes; Douglas Roblin; Marianne Ulcickas Yood; Lawrence S Engel; Andrew Taylor; Joan Fortuny; Laurel A Habel; Christine C Johnson Journal: Int J Cancer Date: 2017-05-15 Impact factor: 7.396
Authors: Sung-Hwan Moon; Chun-Hao Huang; Shauna L Houlihan; Kausik Regunath; William A Freed-Pastor; John P Morris; Darjus F Tschaharganeh; Edward R Kastenhuber; Anthony M Barsotti; Rachel Culp-Hill; Wen Xue; Yu-Jui Ho; Timour Baslan; Xiang Li; Allison Mayle; Elisa de Stanchina; Lars Zender; David R Tong; Angelo D'Alessandro; Scott W Lowe; Carol Prives Journal: Cell Date: 2018-12-20 Impact factor: 41.582
Authors: Jessica L Petrick; Vikrant V Sahasrabuddhe; Andrew T Chan; Michael C Alavanja; Laura E Beane-Freeman; Julie E Buring; Jie Chen; Dawn Q Chong; Neal D Freedman; Charles S Fuchs; John Michael Gaziano; Edward Giovannucci; Barry I Graubard; Albert R Hollenbeck; Lifang Hou; Eric J Jacobs; Lindsay Y King; Jill Koshiol; I-Min Lee; Martha S Linet; Julie R Palmer; Mark P Purdue; Lynn Rosenberg; Catherine Schairer; Howard D Sesso; Alice J Sigurdson; Jean Wactawski-Wende; Anne Zeleniuch-Jacquotte; Peter T Campbell; Katherine A McGlynn Journal: Cancer Prev Res (Phila) Date: 2015-09-21